Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | TSHR | P16473 | 3/20 | 0.46 |
| ▸ | USP2 | O75604 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MMP9 | P14780 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 2/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2383259 | 1.00 | ALDH1A1 (0.46) | ALDH1A1TSHRUSP2LMNAKDM4E | |
| SCHEMBL12944423 | 0.85 | TSHR (0.46) | ALDH1A1TSHRUSP2LMNAKDM4E | |
| SCHEMBL2198401 | 0.79 | ALDH1A1 (0.39) | ALDH1A1TSHRUSP2LMNAKDM4E | |
| SCHEMBL15074098 | 0.79 | ALDH1A1 (0.39) | ALDH1A1TSHRUSP2LMNAKDM4E | |
| SCHEMBL2199578 | 0.77 | ALDH1A1 (0.42) | ALDH1A1TSHRUSP2LMNAKDM4E | |
| SCHEMBL1556220 | 0.77 | — | — | |
| SCHEMBL28081433 | 0.77 | ALDH1A1 (0.43) | ALDH1A1TSHRUSP2LMNAKDM4E | |
| SCHEMBL1556223 | 0.77 | — | — | |
| SCHEMBL1556221 | 0.77 | — | — | |
| SCHEMBL28081352 | 0.77 | ALDH1A1 (0.43) | ALDH1A1TSHRUSP2LMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8293715-B2 | 10a-Azalide compound crosslinked at 10a- and 12-positions | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-10-23 | — | — | US | disclosed |
| US-20110237784-A1 | 10A-AZALIDE COMPOUND CROSSLINKED AT 10A- AND 12-POSITIONS | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-09-29 | — | — | US | disclosed |
| EP-2177526-A1 | 10A-AZALIDE COMPOUND CROSSLINKED AT POSITION-10A AND POSITION-12 | Taisho Pharmaceutical Co. Ltd. (JP) | 2010-04-21 | — | — | EP | disclosed |
| EP-0605729-B1 | OXAZOLIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | TAIHO PHARMACEUTICAL CO LTD (JP) | 2000-07-26 | — | — | EP | disclosed |
| US-5480899-A | ANTILIPEMIC AGENTS | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 1996-01-02 | — | — | US | disclosed |
| EP-0605729-A1 | OXAZOLIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 1994-07-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237784-A1 | 10A-AZALIDE COMPOUND CROSSLINKED AT 10A- AND 12-POSITIONS | DCLRE1A, AZI2, CHD9 | ALDH1A1 2376/4885TSHR 2232/4885USP2 848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.